Wound Healing DelayedNCT05898698
Prospective Case Registry for Wounds
An observational study of Wound Healing Delayed, run by Kerecis Ltd. at 1 site in United States.
Trial summary
This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Wound Healing Delayed
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Mar 2023to 17 Dec 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Ages above 18 less than 90 years of age who have wounds being treated with FSG.
Who may be able to join
- Subjects age 18 and older and are able to provide informed consent.
- Having at least one partial or full thickness wound appropriate for FSG and the wound has NOT received FSG previously.
- Appropriate wounds include: Partial or full thickness wounds, Diabetic foot ulcers, venous leg ulcers, pressure ulcers, chronic vascular ulcers, Trauma wounds (2nd degree burn, abrasions, lacerations, skin tears.
- Surgical wounds (donor sites/grafts, post-Mohs surgery, post Laser surgery, podiatric, wound dehiscence
Who cannot join
- Patient has a 3rd degree burn Patient has a know sensitivity to fish products Patient whose target wound was previously treated with FSG Patient is breastfeeding
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Observational Registry of Safety and Effectiveness of Acellular Fish Skin Grafts in Treatment of Cutaneous Wounds
This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). The registry will be multi-center , target a wide patient population and a variety of wounds to document the quality of wound care, patient outcomes, safety and long-term results.
Read the detailed description
Introduction: This registry will be conducted according to US standards of Good Clinical Practice as adopted by the Food and Drug Administration, associated Federal regulations and applicable institutional research policies and procedures. This study has been approved by a central IRB, WCG IRB in April 2023.
Registry Objectives: The overall objective of the registry is to collect quality and safety data to assess the efficacy of the FSG in treatment of acute and chronic wounds. The ultimate goal of the registry is to enhance quality of care, patient outcomes and establish a resource to facilitate the use of FSG in treatment of acute and chronic wounds.
Primary Objective: The main purpose of the registry is to evaluate the safety and long-term effectiveness of acellular fish skin grafts in treatment of acute and chronic wounds in a real world setting.
Secondary Objective: To evaluate the clinical and financial benefits of FSG in terms of quality of healing, pain and treatment cost.
Research Design: This registry will prospectively collect data from treatment and follow-up of patients who have undergone procedures where wounds are treated with Kerecis FSG. The registry is a non-experiment, multi-center , single arm, open label study to determine real world long-term safety and quality of Kerecis FSG. The study will not be interventional, de-indentified, HIPAA compliant data will only be collected on patients already scheduled to receive the Kerecis product. Subjects will be enrolled as they are scheduled to receive FSG for treatment of their index wound. Subjects will complete follow up as scheduled by their physician and their data will be documented at weekly follow-ups through week 32. Clinical improvement will be collected through case report forms (CRF) at each time point. Subjects will be followed for the 32 weeks but if the Index wound heals before that time , there will be a Healing Confirmation Visit (HCV) 2 weeks after to confirm the Index wound is still healed. If Index wound is not healed at the HCV then the subject will continue to next weekly visit. Index wound assessments will be captured digitally. The depth of the index wound will be collected manually by using a sterilized cotton swab placed in the deepest part of the wound and documenting that measurement. One year form the procedure, patients will receive a survey to evaluate their overall experience and provide any feedback. Overall, the registry is prospective except information regarding patient medical history can be collected retrospectively.
Registry Procedures: Specific Training: Prior to subject enrollment , the Sponsor will initiate in person training with participating sites to provide training to the physicians and their staff about the protocol, registry procedures and data entry. The sponsor will implement a number of strategies to ensure to ensure the quality, consistency and interpretability of data recorded. Training, education and ongoing liason with participating sites will be provided to support high quality data collection.
Data Management and Quality Plan: Data De-identification: Subjects enroll in the registry will be assigned a unique subject identification number. This number will consist of ten characters for the registry protocol number, three digits for a site number and four digits for a sequentially assigned subject number (i.e.,0001, 0002 etc.) Data confidentiality, storage, and Retention: All clinicians and related medical staff involved in looking after patients during the study are bound by medical confidentiality and are obliged to comply with data protection follow all Health Information Portability and Accountability Act of 1996 (HIPAA) and Protected Health Information (PHI). Data will be collected in a CRF and entered into secure, web-based portal databases. The databases are housed and managed in an International Organization for Standardization (ISO) 27001 certified environment. Only authorized users and site administrators can see site wide data. Surgeon users can only see their procedure. The registry will contain built-in exporting function to enable data extraction by participating sites to help clinicians review their practice and improve the services. The paper form CRF will be stored in a locked file cabinet at the participating sites and will be shredded after 7 years post completion of the registry.
Data Quality: The registry will implement several strategies to maintain data quality and consistency such as routine cleaning, quality check and periodic feedback. Training, education and ongoing liason with participating sites will be provided to supporting high quality data collection.
- Conditions
- Wound Healing Delayed
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Endpoint : Complete Wound Closure
Is time and frequency of complete wound closure by or on 32 weeks. Complete closure is referred to as full epithelialization with the absence of drainage.
Measured: 32 weeks
Secondary outcomes (7)
Secondary Endpoints : Reduction in wound area
Proportion of subjects achieving > 60% reduction in wound area from baseline
Measured: 32 weeks
Reduction in wound depth
Proportion of subjects achieving >60% reduction in wound depth from baseline
Measured: 32 weeks
Increase in Vascularization
Proportion of subjects achieving >20% increase in revascularization ( or tissue oxygen saturation) from baseline using noninvasive imaging technique
Measured: 32 weeks
Pain medication use
Proportion of subjects request for pain medication during treatment
Measured: 32 weeks
Number of applications/Cost
Average number of FSG applications and average cost per patient until wound closes
Measured: 32 weeks
Readmission rate
Number of readmission to hospital for index wound related event(s)
Measured: 32 weeks
I year follow-up
12 month outcomes to see if any recurrences at the Index wound
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2023
- Study start17 Mar 2023
- Primary completion17 Mar 2025 (estimated)
- Study completion17 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Wound Healing DelayedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Kerecis Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05898698
- Sponsor's protocol ID
- KS-0790
- Status last verified
- Oct 2024
- First submitted
- 1 Jun 2023
- Last updated
- 30 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Registry of Safety and Effectiveness of Acellular Fish Skin Grafts in Treatment of Cutaneous Wounds
- ClinicalTrials.gov ID
- NCT05898698
- Acronym / sponsor ID
- KS-0790
- Conditions
- Wound Healing Delayed
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Kerecis Ltd.Industry (pharma, biotech, devices)
- Study start
- 17 Mar 2023 (actual)
- Primary completion
- 17 Mar 2025 (estimated)
- Study completion
- 17 Dec 2025 (estimated)
- First posted
- 12 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). The registry will be multi-center , target a wide patient population and a variety of wounds to document the quality of wound care, patient outcomes, safety and long-term results.
Detailed description
Introduction: This registry will be conducted according to US standards of Good Clinical Practice as adopted by the Food and Drug Administration, associated Federal regulations and applicable institutional research policies and procedures. This study has been approved by a central IRB, WCG IRB in April 2023.
Registry Objectives: The overall objective of the registry is to collect quality and safety data to assess the efficacy of the FSG in treatment of acute and chronic wounds. The ultimate goal of the registry is to enhance quality of care, patient outcomes and establish a resource to facilitate the use of FSG in treatment of acute and chronic wounds.
Primary Objective: The main purpose of the registry is to evaluate the safety and long-term effectiveness of acellular fish skin grafts in treatment of acute and chronic wounds in a real world setting.
Secondary Objective: To evaluate the clinical and financial benefits of FSG in terms of quality of healing, pain and treatment cost.
Research Design: This registry will prospectively collect data from treatment and follow-up of patients who have undergone procedures where wounds are treated with Kerecis FSG. The registry is a non-experiment, multi-center , single arm, open label study to determine real world long-term safety and quality of Kerecis FSG. The study will not be interventional, de-indentified, HIPAA compliant data will only be collected on patients already scheduled to receive the Kerecis product. Subjects will be enrolled as they are scheduled to receive FSG for treatment of their index wound. Subjects will complete follow up as scheduled by their physician and their data will be documented at weekly follow-ups through week 32. Clinical improvement will be collected through case report forms (CRF) at each time point. Subjects will be followed for the 32 weeks but if the Index wound heals before that time , there will be a Healing Confirmation Visit (HCV) 2 weeks after to confirm the Index wound is still healed. If Index wound is not healed at the HCV then the subject will continue to next weekly visit. Index wound assessments will be captured digitally. The depth of the index wound will be collected manually by using a sterilized cotton swab placed in the deepest part of the wound and documenting that measurement. One year form the procedure, patients will receive a survey to evaluate their overall experience and provide any feedback. Overall, the registry is prospective except information regarding patient medical history can be collected retrospectively.
Registry Procedures: Specific Training: Prior to subject enrollment , the Sponsor will initiate in person training with participating sites to provide training to the physicians and their staff about the protocol, registry procedures and data entry. The sponsor will implement a number of strategies to ensure to ensure the quality, consistency and interpretability of data recorded. Training, education and ongoing liason with participating sites will be provided to support high quality data collection.
Data Management and Quality Plan: Data De-identification: Subjects enroll in the registry will be assigned a unique subject identification number. This number will consist of ten characters for the registry protocol number, three digits for a site number and four digits for a sequentially assigned subject number (i.e.,0001, 0002 etc.) Data confidentiality, storage, and Retention: All clinicians and related medical staff involved in looking after patients during the study are bound by medical confidentiality and are obliged to comply with data protection follow all Health Information Portability and Accountability Act of 1996 (HIPAA) and Protected Health Information (PHI). Data will be collected in a CRF and entered into secure, web-based portal databases. The databases are housed and managed in an International Organization for Standardization (ISO) 27001 certified environment. Only authorized users and site administrators can see site wide data. Surgeon users can only see their procedure. The registry will contain built-in exporting function to enable data extraction by participating sites to help clinicians review their practice and improve the services. The paper form CRF will be stored in a locked file cabinet at the participating sites and will be shredded after 7 years post completion of the registry.
Data Quality: The registry will implement several strategies to maintain data quality and consistency such as routine cleaning, quality check and periodic feedback. Training, education and ongoing liason with participating sites will be provided to supporting high quality data collection.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Ages above 18 less than 90 years of age who have wounds being treated with FSG.
Key inclusion criteria (4 listed)
- Subjects age 18 and older and are able to provide informed consent.
- Having at least one partial or full thickness wound appropriate for FSG and the wound has NOT received FSG previously.
- Appropriate wounds include: Partial or full thickness wounds, Diabetic foot ulcers, venous leg ulcers, pressure ulcers, chronic vascular ulcers, Trauma wounds (2nd degree burn, abrasions, lacerations, skin tears.
- Surgical wounds (donor sites/grafts, post-Mohs surgery, post Laser surgery, podiatric, wound dehiscence
Key exclusion criteria (1 listed)
- Patient has a 3rd degree burn Patient has a know sensitivity to fish products Patient whose target wound was previously treated with FSG Patient is breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary Endpoint : Complete Wound Closure
Time frame: 32 weeks
Is time and frequency of complete wound closure by or on 32 weeks. Complete closure is referred to as full epithelialization with the absence of drainage.
7 secondary outcomes
Secondary Endpoints : Reduction in wound area
Time frame: 32 weeks
Reduction in wound depth
Time frame: 32 weeks
Increase in Vascularization
Time frame: 32 weeks
Pain medication use
Time frame: 32 weeks
Number of applications/Cost
Time frame: 32 weeks
Readmission rate
Time frame: 32 weeks
I year follow-up
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2024.
- Individual participant dataSharing planned: No
Related trials for Wound Healing Delayed
Active, not recruitingObservational study
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Radiation Toxicity, Chemotherapeutic Toxicity
RecruitingObservational study
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.
Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity
Not yet recruiting
Primary Versus Delayed Wound Closure in Complicated Appendectomy (The HIEDI-Yemen Trial)
Appendicitis, Surgical Wound Infection
RecruitingPhase 1/2
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Not yet recruiting
Delayed Short Dental Implants With Immediate Loading
DENT IMPLANTS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Wound Healing Delayed, run by Kerecis Ltd. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Endpoint : Complete Wound Closure (time frame: 32 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2024.